Clearline Capital’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Clearline Capital’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,946	Closed	-$99.9K	–	132
2023 Q3	$99.9K	Hold	4,946	–	–	0.01%	123
2023 Q2	$129K	Hold	4,946	–	–	0.01%	112
2023 Q1	$103K	Hold	4,946	–	–	0.02%	107
2022 Q4	$101K	Sell	4,946 -17,663	-78%	-$333K	0.02%	117
2022 Q3	$624K	Hold	22,609	–	–	0.07%	112
2022 Q2	$597K	Buy	22,609 +1,976	+10%	+$87.9K	0.08%	105
2022 Q1	$1.65M	Buy	20,633 +14,090	+215%	+$1.74M	0.19%	83
2021 Q4	$1.33M	Buy	+6,543	New	+$1.63M	0.15%	83

Other funds holding VINC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Clearline Capital's VINC Position: Q4 2023 in Review

Clearline Capital sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2023, closing a stake of 4,946 shares — an estimated $99.9K sold.

Clearline Capital first reported a position in VINC in Q4 2021 and held it in 8 quarters. The position peaked at $1.65M in Q1 2022. 32 funds tracked by Wall St. Rank hold VINC as of Q4 2023.

Clearline Capital reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Clearline Capital sold 4,946 Vincerx Pharma, Inc. Common Stock shares in Q4 2023, an estimated $99.9K.
Clearline Capital first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Clearline Capital's Vincerx Pharma, Inc. Common Stock position peaked at $1.65M in Q1 2022.
32 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2023.

Based on Clearline Capital's 13F filing for Q4 2023, filed 14 Feb 2024.